Brief: Medipost receives JP patent
27/12/2017 07:28
Dec 27 (Reuters) - Medipost Co Ltd 078160.KQ :
* Says it received Japan patent on Dec. 27, for TSP-1,
TSP-2,
IL-17BR and HB-EGF associated with stem cell activities and
applications thereof
* Patent number is 2016-63564
Source text in Korean: https://goo.gl/WGBE1o
Further company coverage: 078160.KQ
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 010 62674724;
Reuters Messaging: hedy.cui.reuters.com@reuters.net))
Recent news on Medipost Co
See all newsBrief: Medipost's Cartistem® Meets All Primary And Secondary Endpoints In Japan Phase 3 Trial And Demonstrates Statistically Significant Efficacy Gains Versus Active Control
Brief: Medipost Inc. Submits Ind Amendment With U.S. Food And Drug Administration To Initiate Phase Iii Trial
Brief: Medipost Co Q3 Operating Profit 2 Billion Won, Swings To Profit From Year Earlier
Brief: Medipost To Conduct Capital Increase Of 120 Billion Won
Brief: Medipost Co To Acquire 46 Billion Won Worth Of Shares In Unit Medipost America